Article
Immunology
Zheling Chen, Shanshan Zhang, Ning Han, Jiahong Jiang, Yunyun Xu, Dongying Ma, Lantian Lu, Xiaojie Guo, Min Qiu, Qinxue Huang, Huimin Wang, Fan Mo, Shuqing Chen, Liu Yang
Summary: This study enrolled 7 advanced pancreatic cancer patients and successfully applied neoantigen identification and selection, demonstrating that a personalized neoantigen-based peptide vaccine iNeo-Vac-P01 could improve the clinical efficacy limitations of pancreatic cancer.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Engineering, Biomedical
Yanpu He, Celestine Hong, Samantha J. Fletcher, Adam G. Berger, Xin Sun, Mengdi Yang, Shengnan Huang, Angela M. Belcher, Darrell J. Irvine, Jiahe Li, Paula T. Hammond
Summary: By fusing the peptide with STING Delta TM and complexing it with cGAMP, self-assembled cGAMP-peptide-STING Delta TM tetramers are formed, enabling efficient lymphatic trafficking of the peptide. This strategy acts as a protein carrier for the peptide and a potent adjuvant capable of triggering STING signaling, effectively addressing the challenges in peptide vaccine delivery.
ADVANCED HEALTHCARE MATERIALS
(2022)
Article
Chemistry, Multidisciplinary
Xuedan He, Shiqi Zhou, Wei-Chiao Huang, Amal Seffouh, Moustafa T. Mabrouk, M. Thomas Morgan, Joaquin Ortega, Scott Abrams, Jonathan F. Lovell
Summary: A new vaccine adjuvant system was developed to induce strong cellular immune responses against multiple tumor cell lines, demonstrating durable immunity. The system showed the importance of stable particle formation for effective immune response induction and could control local and metastatic disease in a therapeutic setting.
Article
Pharmacology & Pharmacy
Parvin Zamani, Mohammad Mashreghi, Mahere Rezazade Bazaz, Farshad Mirzavi, Mehdi Barati, Fatemeh Zahedipour, Mahmoud Reza Jaafari
Summary: The study showed that a liposomal-based peptide vaccine containing AE36, PADRE, and MPL could induce significant immune responses and potential prophylactic vaccine candidacy in a mouse model of breast cancer.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Immunology
Sofie Kirial Mork, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhoj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmstroem, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Norgaard, Lars Vibe Andreasen, Grith Kroyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Summary: This study evaluated the tolerability and safety of a vaccine using Bcl-XL-peptide and CAF((R))09b as an adjuvant in patients with hormone-sensitive prostate cancer. The optimal route of administration and vaccine immunogenicity were also assessed. The vaccine was found to be feasible and safe, and it was able to induce immune responses. IP administration led to earlier and stronger vaccine-specific immune responses compared to IM administration.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Ben Wylie, Ferrer Ong, Hanane Belhoul-Fakir, Kristin Priebatsch, Heique Bogdawa, Anja Stirnweiss, Paul Watt, Paula Cunningham, Shane R. Stone, Jason Waithman
Summary: This study enhanced the effectiveness of cancer vaccines by adding a short cell penetrating peptide sequence to the vaccine construct, showing improved outcomes in both viral and cancer models. Targeting cross-presenting dendritic cells with a novel vaccine strategy led to robust expansion of antigen-specific T cells and protective immunity against viral infection, as well as slowed tumor outgrowth in a melanoma model, suggesting the generation of antigen-specific anti-tumor immunity.
Article
Engineering, Biomedical
Qiu-Ling Zhang, Sheng Hong, Xue Dong, Di-Wei Zheng, Jun-Long Liang, Xue-Feng Bai, Xia-Nan Wang, Zi-Yi Han, Xian-Zheng Zhang
Summary: This study presents a strategy for simplifying antigen presentation by extracellular degradation of antigen proteins into peptides, leading to improved utilization of cancer antigens and enhanced cancer immunity. The approach demonstrates potential for personalized anti-cancer therapy and has implications for expanding immunology fields and translational medicine.
Review
Immunology
Alexander J. Stephens, Nicola A. Burgess-Brown, Shisong Jiang
Summary: Peptide-based cancer vaccines rely on strong activation of adaptive immune response but have not yet proven to be effective in clinical settings. To overcome limitations, vaccine designs are becoming more personalized and combined with existing cancer treatments.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Xueyuan Yang, Weizhong Zhang, Wen Jiang, Anil Kumar, Shiyi Zhou, Zhengwei Cao, Shuyue Zhan, Wei Yang, Rui Liu, Yong Teng, Jin Xie
Summary: The study introduces a composite nanoparticle that can co-deliver a photosensitizer and an IDO inhibitor, showing significantly improved tumor suppression and animal survival in vivo. The treatment increases tumor infiltration of CD8(+) T cells while decreasing the frequencies of MDSCs and Tregs, highlighting the potential for combination therapy.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)
Review
Chemistry, Medicinal
Muhammad Luqman Nordin, Ahmad Khusairi Azemi, Abu Hassan Nordin, Walid Nabgan, Pei Yuen Ng, Khatijah Yusoff, Nadiah Abu, Kue Peng Lim, Zainul Amiruddin Zakaria, Noraznawati Ismail, Fazren Azmi
Summary: Breast cancer is the second-leading cancer globally, and immunotherapy via vaccine has gained attention for its specific and targeted immune cell activity against the disease. Peptide-based vaccines, despite their vulnerabilities, can be customized and improved with carriers to induce a specific immune response. Nanotechnology advancements allow the incorporation of other components into peptide-based vaccines, modulating the immune response against breast cancer.
Article
Oncology
Masanori Noguchi, Kiyohide Fujimoto, Gaku Arai, Hiroji Uemura, Katsuyoshi Hashine, Hiroaki Matsumoto, Satoshi Fukasawa, Yasuo Kohjimoto, Hideomi Nakatsu, Atsushi Takenaka, Masato Fujisawa, Hirotsugu Uemura, Seiji Naito, Shin Egawa, Hiroyuki Fujimoto, Shiro Hinotsu, Kyogo Itoh
Summary: This study investigated the impact of personalized peptide vaccination (PPV) on overall survival (OS) in HLA-A24-positive patients with castration-resistant prostate cancer (CRPC) who failed docetaxel chemotherapy. The results showed that PPV did not prolong OS overall, but subgroup analysis revealed survival benefits in patients with a lower proportion of neutrophils or a higher proportion of lymphocytes at baseline.
Article
Engineering, Biomedical
Huijuan Song, Qi Su, Yu Nie, Chuangnian Zhang, Pingsheng Huang, Shengbin Shi, Qiang Liu, Weiwei Wang
Summary: Vaccination has shown great potential in cancer immunotherapy, but achieving strong and broad therapeutic CD8 T cell immunity against tumors is challenging due to tumor heterogeneity. In this study, a bioinspired nanofibrous trivalent peptide hydrogel vaccine was constructed to mimic the structure and function of the extracellular matrix. The vaccine effectively stimulated CD8 T cell response and inhibited tumor growth in mice. This approach offers a simple and versatile platform for the development of personalized cancer vaccines.
ACTA BIOMATERIALIA
(2023)
Article
Immunology
Fatemeh Zahedipour, Khadijeh Jamialahmadi, Parvin Zamani, Mahmoud Reza Jaafari
Summary: Peptide vaccines have shown potential in cancer immunotherapy by targeting tumor antigens and activating the immune system, but their efficacy is still a major challenge. This review discusses the current status and strategies to improve the efficacy of peptide vaccines, including the use of novel adjuvants, neoantigens, nano-delivery systems, and combination therapies. Personalized cancer vaccines, multivalent peptides, conjugated peptides, fusion proteins, and self-assembled peptides are also highlighted as ways to enhance the immunogenicity of peptide vaccines. Combining peptide vaccines with other immunotherapeutic approaches and developing personalized vaccines can significantly improve their efficacy and clinical outcomes for cancer patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Ines Lecoq, Katharina L. Kopp, Marion Chapellier, Panagiotis Mantas, Evelina Martinenaite, Maria Perez-Penco, Lars Ronn Olsen, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen
Summary: This study identified CCL22 as a potential target for immunotherapy by showing that vaccination with CCL22-derived peptides induced specific T-cell responses and had anti-tumor effects in mouse models. The vaccination also modulated the immune cell composition in the tumor microenvironment, increasing the infiltration of CD8+ cells and M1 macrophages, and altering the immune cell ratios. These findings provide a rationale for the development of CCL22-targeting immunotherapy in cancer.
Article
Engineering, Biomedical
Yixuan Guo, Yu Liu, Wei Wu, Daishun Ling, Qiao Zhang, Peng Zhao, Xi Hu
Summary: This article will discuss different types of IDO inhibitors and relevant clinical trials, especially feasible combined therapeutic modalities. In addition, it will also review cutting-edge nanomedicines that combine IDO inhibitors with other therapeutic modalities to effectively enhance the effectiveness of cancer therapy. Finally, the prospects of IDO inhibitors in clinical application and potential breakthroughs will be briefly discussed.
Article
Oncology
Eva Ellebaek, Aimilia Schina, Henrik Schmidt, Charlotte Aaquist Haslund, Lars Bastholt, Inge Marie Svane, Marco Donia
Summary: This study found that initiation of immunotherapy in summer is associated with prolonged survival in patients with BRAF wild-type melanoma in Denmark.
PIGMENT CELL & MELANOMA RESEARCH
(2023)
Review
Immunology
Mads Hald Andersen
Summary: Identifying and characterizing tumor antigens are crucial for developing anti-cancer immunotherapy. Traditional tumor-associated antigens (TAAs) are mainly expressed in tumor cells, while tumor-specific antigens (TSAs) are unique to tumor cells. Recent studies have focused on patient-specific neoantigens, which are highly immunogenic due to their absence in normal tissues. In addition, the discovery of anti-regulatory T cells (anti-Tregs) has led to the identification of tumor microenvironment antigens (TMAs) that can be targeted for immunotherapy. TMAs not only directly attack tumor cells but also modulate the tumor microenvironment, making it more immunocompetent and hostile to tumors. Unlike TAAs and TSAs, TMAs are also expressed in non-transformed cells, providing the opportunity to affect tumors with low levels of surface human leukocyte antigen (HLA) expression. This review discusses the characteristics, differences, and advantages of TMAs compared to traditional tumor antigens and highlights the potential of using TMAs in immune modulatory vaccines as a promising approach to immunotherapy.
SEMINARS IN IMMUNOPATHOLOGY
(2023)
Editorial Material
Infectious Diseases
Mads Hald Andersen
Article
Biochemical Research Methods
Anders H. Kverneland, Ole Ostergaard, Kristina Bennet Emdal, Inge Marie Svane, Jesper Velgaard Olsen
Summary: This study demonstrates that enrichment of extracellular vesicles (EVs) by ultracentrifugation can significantly increase the depth of the plasma proteome analysis. By optimizing the workflow, over two thousand proteins can be quantified in a short time using label-free quantification and data independent acquisition (DIA), enabling high-throughput analysis of plasma samples and supporting potential biomarker discovery in the future.
Article
Medicine, General & Internal
Nicklas Juel Spindler, Gitte Fredberg Persson, Susann Theile, Dorte Lisbeth Nielsen, Estrid Hogdall, Gina Al-Farra, Helle Westergren Hendel, Torben Lorentzen, Inge Marie Svane, Henriette Lindberg, Rikke Lovendahl Eefsen
Summary: This study aims to investigate the efficacy of combining SBRT and CPI treatment in patients with mCRPC. A total of 80 evaluable patients who have progressed after multiple lines of treatment will be enrolled and receive ipilimumab and nivolumab combination therapy, with some patients also receiving SBRT. The primary endpoints are objective response rate and PSA response rate, and secondary endpoints include safety, radiographic progression-free survival, clinical benefit rate, duration of response, PSA-progression-free survival beyond 12 weeks, quality of life, and overall survival. The results will be published in an international peer-reviewed journal.
Article
Oncology
Amalie Valentin, Anne Kirstine Hundahl Moller, Jesper Andreas Palshof, Bo Broberg, Eva Gravesen, Inge Marie Svane, Ditte Hansen
Summary: This study aimed to describe the incidence and causes of AKI in patients treated with immune checkpoint inhibitors. The study showed that 16% of malignant melanoma patients and 25% of metastatic renal cell carcinoma patients developed AKI. Some of these cases may be related to immune checkpoint inhibitors or the use of proton pump inhibitors.
Letter
Gastroenterology & Hepatology
Emilie Dahl, Osama Abed, Jorgen Agnholt, Jacob Bjerrum, Anders Dige, Jens Kjeldsen, Inge Svane, Marco Donia, Jakob Seidelin
Summary: This article is linked to Dahl et al papers. To view these articles, visit...
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Neel Maria Helvind, Marie Brinch-Moller Weitemeyer, Annette Hougaard Chakera, Helle Westergren Hendel, Eva Ellebaek, Inge Marie Svane, Mette Wanscher Kjaerskov, Sophie Bojesen, Helle Skyum, Soren Kjaer Petersen, Lars Bastholt, Christoffer Johansen, Pernille Envold Bidstrup, Lisbet Rosenkrantz Holmich
Summary: This study aimed to determine the impact of surveillance with routine FDG PET-CT on hazard, cumulative incidence, and absolute risk of overall, locoregional, and distant recurrence detection in patients with stage IIB to IIID cutaneous melanoma. The study found that patients with stage IIB to IIID melanoma followed with routine FDG PET-CT had a 51% increased hazard of distant recurrence detection within the first two years of surveillance.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Arianna Draghi, Mario Presti, Agnete W. P. Jensen, Christopher A. Chamberlain, Benedetta Albieri, Anne-Christine K. Rasmussen, Mads H. Andersen, Michael D. Crowther, Inge Marie Svane, Marco Donia
Summary: Our study demonstrates that exploiting tumor-specific cytotoxic CD4(+) TILs could help overcome resistance to ICB mediated by IFN gamma-signaling loss in MHCIIconst(+) melanomas.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Immunology
Mads Hald Andersen
SEMINARS IN IMMUNOPATHOLOGY
(2023)
Article
Immunology
Sofie Kirial Mork, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhoj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmstroem, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Norgaard, Lars Vibe Andreasen, Grith Kroyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Summary: This study evaluated the tolerability and safety of a vaccine using Bcl-XL-peptide and CAF((R))09b as an adjuvant in patients with hormone-sensitive prostate cancer. The optimal route of administration and vaccine immunogenicity were also assessed. The vaccine was found to be feasible and safe, and it was able to induce immune responses. IP administration led to earlier and stronger vaccine-specific immune responses compared to IM administration.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Thomas Morgan Hulen, Christina Friese, Nikolaj Pagh Kristensen, Joachim Stoltenborg Granhoj, Troels Holz Borch, Marlies J. W. Peeters, Marco Donia, Mads Hald Andersen, Sine Reker Hadrup, Inge Marie Svane, Ozcan Met
Summary: Checkpoint inhibition (CPI) therapy and adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL-based ACT) have shown to be highly effective immunotherapies for metastatic melanoma treatment. In this study, we investigated the changes in TIL qualities when the ex vivo microenvironment of intact tumor fragments were modulated with checkpoint inhibitors targeting PD-1 and CTLA-4. We found that unmodified TILs from CPI-resistant individuals could be produced, were terminally differentiated, and capable of responding to tumor. Furthermore, we confirmed the specificity of TILs to highly responding tumor antigens and identified the contribution of specific CD39(+)CD69(+) terminally differentiated populations.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Genetics & Heredity
Annie Borch, Anne-Mette Bjerregaard, Vinicius Araujo Barbosa de Lima, Olga Ostrup, Christina Westmose Yde, Aron Charles Eklund, Morten Mau-Sorensen, Carolina Barra, Inge Marie Svane, Finn Cilius Nielsen, Samuel A. Funt, Ulrik Lassen, Sine Reker Hadrup
Summary: Immune checkpoint inhibition has revolutionized cancer treatment, but only a fraction of patients respond to this therapy. Identifying biomarkers is crucial for selecting patients who will benefit from treatment. Our study revealed that patients with higher neoepitope load, higher expression of T cell signatures, and higher PD-L2 expression had better clinical outcomes. Combining these biomarkers improves prediction of treatment efficacy.
FRONTIERS IN GENETICS
(2023)
Article
Oncology
Rasmus Erik Johansson Mortensen, Morten Orebo Holmstrom, Thomas Landkildehus Lisle, Jane P. Hasselby, Gro L. Willemoe, Ozcan Met, Inge Marie Svane, Julia Johansen, Dorte L. Nielsen, Inna M. Chen, Mads Hald Andersen
Summary: This study investigated the significance of TGF-beta-specific T-cell immunity in patients with pancreatic cancer treated with ICI combined with radiotherapy. The results showed that patients with a strong TGF-beta-specific immune response had longer progression-free and overall survival compared to those with a weak or no response. It was also found that TGF-beta-specific T cells could recognize and enhance immune responses. Thus, combining TGF-beta vaccination with ICI/radiotherapy may benefit patients with pancreatic cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Cathrine Lund Lorentzen, Julie Westerlin Kjeldsen, Eva Ehrnrooth, Mads Hald Andersen, Inge Marie Svane
Summary: Summary: This study presented the long-term follow-up results of the IDO/PD-L1 vaccine and nivolumab combination therapy in cohort A, showing promising efficacy with high overall response rates and durable responses. However, cohort B did not show significant clinical effects.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)